Patients with small-cell lung cancer should explore clinical trials for promising new therapies

Big changes in “small-cell lung-cancer” give patients options they never had before. “Small-cell lung-cancer” is the deadliest of all the types of lung-cancer; lung-cancer kills more people than breast-, prostate-, and colon-cancer, combined. The good news? Because of research, there are more targeted and personalized treatments. “Small-cell lung-cancer” is different from the most-common form of lung-cancer, “non-small-cell lung-cancer”; it’s more aggressive, and is commonly linked with smokers. But, there is hope—with many new therapies in the pipeline. Doctor Triparna Sen—of “Icahn School of Medicine at Mount Sinai”—is on the frontlines… “Do we have targets? Yes, we do have targets. Do they look promising? Yes, they do look promising. It will not be ‘one size fits all’.” Patients who have finished their initial treatment now have new options, and should talk to their doctor about the latest clinical-trials—where they can receive tomorrow’s treatment, today. You can find out about the latest research from “Lung-Cancer Foundation of America”, at “l-c-f-america”-dot-org.